Uncoupling of CSF biomarkers and clinical status in patients with a novel mutation of ATP13a2
Stephani, C.; Ewers, D.; Stausberg, D.; Rasche, D.; Bahiraee, A.; Ahmad, B.; Baehr, M.; Downie, B.; Hirschel, S.; Pauli, S. J.; Riedel, C.; Sachkova, A.; Salinas, G.; Schneider, A.; Riesen, C. v.; Wollnik, B.; Yigit, G.; Nave, K.; Zerr, I.; Eggert, S.; Sereda, M. W.
Show abstract
Cerebrospinal fluid (CSF) biomarkers are generally assumed to reflect the severity and progression of neurodegenerative disease. We report three siblings carrying a novel heterozygous ATP13A2 variant (p.Pro629Ser) who challenge this paradigm. Despite only slowly progressive cognitive decline, axonal neuropathy, and leukodystrophy on MRI, all established CSF markers of neuronal destruction were profoundly abnormal, with tau and phosphorylated tau levels exceeding even those seen in Alzheimers disease or Creutzfeldt- Jakob disease. Patient fibroblasts revealed lysosomal alterations and abnormal amyloid precursor protein processing, and CSF polyamine levels were strongly reduced, consistent with impaired ATP13A2 function. These cases define a new ATP13A2-associated phenotype and, most importantly, demonstrate a striking dissociation between biomarker profiles and clinical course, questioning the general validity of CSF markers as direct indicators of disease severity.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Essential tremor with tau pathology features seeds indistinguishable in conformation from Alzheimer's disease and primary age-related tauopathy 95%
- Genome-wide association study and functional validation implicates JADE1 in tauopathy 94%
- Tau phosphorylated at serine 356 is associated with Alzheimer's disease pathology and can be lowered in mouse and human brain tissue using the NUAK inhibitor WZ4003 93%
Similar papers in this journal
- Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression 93%
- Nigral pathology contributes to microstructural integrity of striatal and frontal tracts in Parkinson's disease 93%
- Synaptic loss in primary tauopathies revealed by UCB-J positron emission tomography. 93%
Similar papers in this journal
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.